IRVINE, Calif.—Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), a biopharmaceutical company focused on therapeutic eyecare, announced positive financial results for the first quarter of 2026, reporting new product sales of $145.4 million, compared with $78.3 million for the same period in 2025, driven by higher volume and improvements in the gross-to-net discount. “Xdemvy is driving a fundamental shift in how Demodex blepharitis (DB) is diagnosed and treated,” said Bobak Azamian, MD, Ph.D., chief executive officer and chairman of Tarsus.